Articles

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis

Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, ItalyDepartment of Molecular Medicine, University of Pavia, Pavia, Italy
Transfusion Medicine Service, Melegnano Hospital, Vizzolo Predabissi, ItalyDept. of Computer Engineering and System Science, University of Pavia, Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, ItalyDepartment of Molecular Medicine, University of Pavia, Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, ItalyDepartment of Molecular Medicine, University of Pavia, Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, ItalyDepartment of Molecular Medicine, University of Pavia, Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, ItalyDepartment of Molecular Medicine, University of Pavia, Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, ItalyDepartment of Molecular Medicine, University of Pavia, Pavia, Italy;Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Italy
Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, ItalyDepartment of Molecular Medicine, University of Pavia, Pavia, Italy
Vol. 98 No. 3 (2013): March, 2013 https://doi.org/10.3324/haematol.2012.073593